This article is a correction to:
The use of plasma exchange with albumin replacement in the management of Alzheimer’s disease: a scoping review
Yahveth Cantero-Fortiz1,2*†‡
Mercè Boada1,2†‡- 1Ace Alzheimer Center Barcelona, Universitat Internacional de Catalunya, Barcelona, Spain
- 2Networking Research Center on Neurodegenerative Diseases (CIBERNED), Instituto de Salud Carlos III, Madrid, Spain
A corrigendum on
The use of plasma exchange with albumin replacement in the management of Alzheimer's disease: a scoping review
by Cantero-Fortiz, Y., and Boada, M. (2024). Front. Neurol. 15:1443132. doi: 10.3389/fneur.2024.1443132
In the published article, there was an error regarding the significance of the results using “p < 0.05” instead of “p > 0.05.” Despite the Clinical relevance, there was no statistical significance.
A correction has been made to the Results section, subsection Neuropsychological and quality-of-life section assessments, paragraph 26. The sentence originally stated:
“The study employed standardized tests such as the Mini-Mental State Examination (MMSE) and the AD Disease Assessment Scale-Cognitive Subscale (ADAS-Cog) which showed statistically significant improvements (p < 0.05) in the treatment group over the 21 weeks treatment period plus 6 months follow-up.”
The correct sentence should be:
“The study employed standardized tests such as the Mini-Mental State Examination (MMSE) and the Alzheimer's Disease Assessment Scale-Cognitive Subscale (ADAS-Cog) which demonstrated clinical improvements in the treatment group. However, these improvements did not reach statistical significance (p > 0.05) over the 21-week treatment period plus 6 months of follow-up.”
Additionally, the term “AD disease” was used redundantly in several paragraphs.
A correction has been made throughout the article, [Paragraphs 11, 12, 14, 20, 21, 22, 26, and 35]. These sentences previously stated:
“AD disease”
The corrected sentences now state:
“AD”
The authors apologize for these errors and state that this does not change the scientific conclusions of the article in any way. The original article has been updated.
Publisher's note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.
Keywords: Alzheimer's disease, plasma exchange, albumin replacement, cognitive function, amyloid-beta, neurodegenerative disorders
Citation: Cantero-Fortiz Y and Boada M (2024) Corrigendum: The use of plasma exchange with albumin replacement in the management of Alzheimer's disease: a scoping review. Front. Neurol. 15:1509655. doi: 10.3389/fneur.2024.1509655
Received: 11 October 2024; Accepted: 16 October 2024;
Published: 29 October 2024.
Edited and reviewed by: Iván Murrieta-Álvarez, Baylor College of Medicine, United States
Copyright © 2024 Cantero-Fortiz and Boada. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
*Correspondence: Yahveth Cantero-Fortiz, ycantero@fundacioace.org
†These authors have contributed equally to this work
‡ORCID: Yahveth Cantero-Fortiz orcid.org/0000-0003-0329-6487
Mercè Boada orcid.org/0000-0003-2617-3009